Please login to the form below
inhaled insulin
This page shows the latest inhaled insulin news and features for those working in and with pharma, biotech and healthcare.
Sanofi abandons inhaled insulin pact with Mannkind
Sanofi has handed back rights to inhaled insulin drug Afrezza to Mannkind, less than a year after its launch, after the diabetes treatment saw underwhelming sales. ... The disappointing performance of the drug also promoted other inhaled insulin
Latest news
-
AstraZeneca and its diabetes plans
oral and inhaled insulin. ... I think the jury is out on inhaled insulin,” he says.
-
Sanofi's CEO search ends as Bayer's Brandicourt takes the job
As Viehbacher's replacement Brandicourt faces a number of challenges, including the impending loss of patent protection for Sanofi big-selling diabetes therapy Lantus (insulin glargine). . ... The company also has a number of key product launches
-
Sanofi launches inhaled insulin in US
Partners with MannKind on only diabetes treatment of its kind. . The device Afrezza will be distributed in. Sanofi has launched what will be the only inhaled insulin available to treat people ... Afrezza is the only product of its kind available in the
-
Sanofi cuts $925m deal for MannKind's inhaled insulin
French company bolsters diabetes business with Afrezza collaboration. This inhaler is designed to be used with Mannkind's inhaled insulin Afrezza. ... MannKind's search for a partner for its recently approved inhaled insulin therapy Afrezza has ended
-
Third time lucky as MannKind's inhaled insulin is approved
US FDA backs new diabetes treatment Afrezza. An inhaled formulation of insulin for diabetes could be back on the market shortly after the US FDA approved MannKind's Affrezza. ... Afrezza is a short-acting inhaled insulin, a group which represents around
More from news
Approximately 4 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2016
It was a big news month for Sanofi, also in the news for terminating its licensing deal with MannKind for Afrezza (inhaled insulin). ... 150. MannKind/ Receptor Life Sciences. Licence, collaboration. Multiple inhaled therapeutic products for conditions
-
Oral biologics delivery still elusive
The only alternative to injections of the hormone at the moment is Mannkind's inhaled insulin Afrezza - partnered with Sanofi - which has not gained much momentum yet in the marketplace with ... like peptide-1 (GLP-1), a hormone that works independently
-
Going the distance
The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... The drug-device combination delivers a dry formulation of human insulin via a small and portable inhaler, similar to those associated with
-
Deal Watch table for August 2014
8, 300. MannKind/ Sanofi. Licence. Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US).
-
Pharma deals during August 2014
the leading pack diabetes drug companies, to ignore any lurking concerns caused by Pfizer's woeful experience with inhaled insulin (Exubera) and jump into this precarious game with MannKind. . ... The drug-device combination consists of a dry
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Nucleus Global announces a trio of promotions
- UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
